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Abstract
Background: Cytokines play an important role in the development of diabetic chronic renal insufficiency (CRI). Transforming
growth factor β1 (TGF β1) induces renal hypertrophy and fibrosis, and cytokines like tumor necrosis factor-alpha (TNFα),
chemoattractant protein-1 (MCP-1), and regulated upon activation and normal T cell expressed and secreted (RANTES) mediate
macrophage infiltration into kidney. Over expression of these chemokines leads to glomerulosclerosis and interstitial fibrosis.
The effect of MCP-1 and RANTES on kidney is conferred by their receptors i.e., chemokine receptor (CCR)-2 and CCR-5
respectively. We tested association of nine single nucleotide polymorphisms (SNPs) from TGFβ1, TNFα, CCR2 and CCR5
genes among individuals with type-2 diabetes with and without renal insufficiency.
Methods: Type-2 diabetes subjects with chronic renal insufficiency (serum creatinine ≥ 3.0 mg/dl) constituted the cases, and
matched individuals with diabetes of duration ≥ 10 years and normoalbuminuria were evaluated as controls from four centres
in India. Allelic and genotypic contributions of nine SNPs from TGFβ1, TNFα, CCR2 and CCR5 genes to diabetic CRI were
tested by computing odds ratio (OR) and 95% confidence intervals (CI). Sub-analysis of CRI cases diabetic retinopathy status as
dependent variable and SNP genotypes as independent variable in a univariate logistic regression was also performed.
Results:  SNPs Tyr81His and Thr263Ile in TGF β1 gene were monomorphic, and Arg25Pro in TGF β1 gene and Δ32
polymorphism in CCR5 gene were minor variants (minor allele frequency <0.05) and therefore were not considered for case-
control analysis. A significant allelic association of 59029G>A SNP of CCR5 gene has been observed and the allele 59029A seems
to confer predisposition to development of diabetic CRI (OR 1.39; CI 1.04–1.84). In CRI subjects a compound group of
genotypes "GA and AA" of SNP G>A -800 was found to confer predisposition for proliferative retinopathy (OR 3.03; CI 1.08–
8.50, p = 0.035).
Conclusion: Of the various cytokine gene polymorphisms tested, allele 59029A of CCR5 gene is significantly associated with
diabetic renal insufficiency among Asian Indians. Result obtained for 59029G>A SNP of CCR5 gene is in conformity with reports
from a Japanese population but due to sub-optimal power of the sample, replication in larger sample set is warranted.
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Background
Lifestyle and overeating with consequent obesity are
major triggering factors for type-2 diabetes epidemic but
important underlying pathogenic elements appear to be
genetic factors. Positive family history confers a 2.4 fold
increased risk and 15–25% of first degree relatives of
patients with type-2 diabetes develop impaired glucose
tolerance. The lifetime risk for type-2 diabetes is 38% if
one parent has diabetes and 60% if both the parents are
affected [1]. Multiple susceptibility genes have been
reported in pathogenesis of type-2 diabetes as well as dia-
betic complications such as nephropathy. Clinical dia-
betic nephropathy results from glomerular, tubular,
interstitial and vascular lesions. Genesis of diabetic kidney
disease involves both hemodynamic and metabolic path-
ways and a subset of diabetic patients who develop neph-
ropathy may have a genetic susceptibility to develop renal
injury in response to abnormal physiological milieu that
is associated with diabetes. There is interplay of meta-
bolic, biochemical and hemodynamic abnormalities that
contribute to development of diabetic renal disease and it
has been proposed that renin-angiotensin-aldosterone
system (RAAS), nitric oxide, and transforming growth fac-
tor (TGF)-β1 pathways are important [2].
As a part of an extensive analysis of genetic susceptibility
to diabetic renal disease, we had earlier reported the role
of RAAS gene polymorphisms in diabetic CRI. A highly
significant association of Met235Thr, and a weaker associ-
ation of T>C (-344) and G>A (-1903) SNPs with CRI,
independent of hypertension, was observed there in [3]. It
suggested that the effect of RAAS may not be mediated
through modulation of hypertension as a crucial mecha-
nism for development of CRI but it may operate by stim-
ulation of chemokines like transforming growth factor β1
(TGFβ1), tumor necrosis factor α (TNFα) and interleukin
1 (IL1). Hyperglycemia and systemic hypertension leads
to glomerular hypertension as a result of ineffective pre-
glomerular resistances, which are possibly genetically
determined [4,5]. Glomerular hypertension in early stages
of nephropathy leads to changes in endothelial and
mesangial cells. The resultant increased expression of glu-
cose transporter-1 (GLUT-1) leads to increased produc-
tion of TGFβ1 and formation of advanced glycation end-
products (AGE) and its receptor [6,7]. This promotes dep-
osition of collagens I, III and fibronectin. Activation of
mitochondrial protein kinase-C (PKC) also leads to pro-
duction of TGFβ1, superoxide and peroxynitrite and
decreases activity of nitric oxide. This decreased activity
increases angiotensin II and angiotensinogen II type-1
receptor which loop back upstream in the cascade increas-
ing glomerular hypertension and expression of TGFβ1
and GLUT-1 thereby continuing the vicious cycle of
glomerular injury [2]. In addition, angiotensin II also acti-
vates PKC and MAPK pathways, which are abundantly
implicated in activation of TGFβ1, TNFα and IL1, in vari-
ous cells [8-11]. Over expression of TNFα and IL-1 stimu-
lates the expression of chemokines like monocyte
chemoattractant protein1 (MCP1) and "Regulated upon
activation and normal T cell expressed and secreted"
(RANTES) in human mesangial cells [12-14]. Up regula-
tion of MCP1 and RANTES triggers recruitment of mono-
cytes and macrophage infiltration in glomerulus of
diabetic rats [15] and DN subjects [16]. Chemokine recep-
tors, CCR2 and CCR5, are the major receptors for MCP1
and RANTES respectively and are expressed on the surface
of monocytes. Wada et al [17] have reported that CCR5
positive cells were detected in both the glomeruli and the
interstitium of human crescentic glomerulonephritis
(GN) and therefore, it is speculated that CCR2 and CCR5
might be involved in the recruitment of macrophages in
human DN. CCR2 and CCR5 mediated monocyte recruit-
ment and differentiation to macrophage in the glomeru-
lus and interstitium has been speculated to play a role in
development of glomerulosclerosis and fibrosis in pro-
gressive diabetic kidney disease [18]. Considering such
importance of inflammatory genes in development and
progression of diabetic renal disease, we tested association
of nine SNPs from TGFβ1, TNFα, CCR2, and CCR5 genes
with diabetic chronic renal insufficiency (CRI) using a
case-control design.
Methods
Subjects
Ethical committee clearance for the study was obtained
from the participating medical institutions and universi-
ties. In this case-control study, consecutive subjects suffer-
ing from type-2 diabetes with CRI (cases, CRI, n = 196)
and diabetics without any evidence of diabetic kidney dis-
ease (controls, DM, n = 225) were recruited (after obtain-
ing written informed consent from the study subjects)
from the outpatient departments of the four participating
medical institutions situated across the country. These
included MS Ramiah Medical College (Bangalore), All
India Institute of Medical Sciences (New Delhi), Jaipur
Diabetes and Research Centre (Jaipur), and Monilek Hos-
pital and Research Centre (Jaipur). The research carried
out on study subjects was in compliance with the Helsinki
Declaration [19]. Diabetes was diagnosed on the basis of
World Health Organization guidelines. Demographic
details and clinical profile of the study population have
been described earlier ([3]; See additional file 1). In brief,
inclusion criteria for the CRI group (cases) were subjects
with type-2 diabetes of ≥ 2 years, serum creatinine ≥ 3 mg/
dl, urinary albumin excretion rate (AER) > 200 mg/l and
presence of diabetic retinopathy. Patients with drug
induced nephrotoxic damage or secondary causes of albu-
minuria such as obstructive renal disease, renal stone dis-
ease and acute urinary tract infection were excluded.
Normoalbuminuric (AER<20 mg/l) individuals with type-BMC Medical Genetics 2007, 8:20 http://www.biomedcentral.com/1471-2350/8/20
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2 diabetes of ≥ 10 years duration (average 17.07 ± 6.69
years) were recruited as control subjects.
Genetic analysis
DNA from venous blood was isolated using phenol-chlo-
roform method and used for genetic analysis. A total of
nine SNPs namely -800 G>A, -509 C>T, Arg25Pro,
Tyr81His and Thr263Ile in TGFβ1gene, G>A (-308) in
TNFα, Val64Ile in CCR2 gene, and CCR5Δ32 and 59029
G>A in CCR5 gene, were genotyped using the polymerase
chain reaction-restriction fragment length polymorphism
(PCR-RFLP) approach. Primers for all the SNPs were
designed using Primer 3 software. Details including loca-
tion of SNPs in the respective genes, primer sequences,
PCR conditions and restriction enzyme with product sizes
are presented in Table 1. The digested PCR products were
resolved on 2–3% agarose gels stained with ethidium bro-
mide.
Statistical analysis
Difference in continuous and nominal clinical variables
among DM (controls) and diabetic CRI (cases) groups
was compared using t-test and χ2 tests respectively. Hardy
Weinberg equilibrium (HWE) was tested for each SNP
using the data obtained by genotyping about 200 healthy,
non-diabetic individuals from different states of India
[unpublished data]. Pair wise linkage disequilibrium
between multiple SNPs of a gene was calculated using
EMLD Software [20]. Allelic and genotypic associations at
each of the SNPs were tested using Pearson's χ2 test and
calculation of odds ratio (OR). Power of sample size was
calculated using PAWE software [21,22]. Pair wise interac-
tions between SNPs were assessed using logistic regression
analysis. Cumulative effect of different clinical variables
and SNPs was also tested by logistic and linear regression
analyses using SPSS. P values < 0.05 were considered sig-
nificant.
Results
Clinical details of the subjects included in the study are
reported and discussed somewhere else ([3]; See addi-
tional file 1). In brief, No significant difference was
observed in body-mass index, total serum cholesterol and
triglyceride levels between the DM and CRI groups (p >
0.05). However, serum creatinine and blood pressure and
proportion of hypertensive individuals and those with
diabetic retinopathy were significantly greater (p < 0.05)
among diabetic CRI subjects compared to DM controls.
Genetic analysis
TGFβ1
Of the five SNPs selected for genotyping in this gene, two
SNPs namely, Tyr81His and Thr263Ile were monomor-
phic and Arg25Pro was a minor variant (allele frequency
of variant allele= 0.01) and therefore not analysed further.
Since the r2 value between G>A -800 and C>T -509 SNPs
(D' = 0.99, r2 = 0.05) was not significant both of these
were genotyped in the case-control population. Neither of
these two SNPs showed ether allelic or genotypic associa-
tion (Table 2).
TNFα
No allelic or genotypic association of G>A (-308) pro-
moter SNP of the gene with CRI was observed in this study
(Table 2).
CCR2
No allelic or genotypic association of Val64Ile with CRI
was observed in this study (Table 2).
CCR5
A significant association of allele 'A' of 59029 G>A SNP
with CRI was observed (OR 1.39, CI 1.04–1.84, p = 0.02).
CCR5Δ32 polymorphism was only a minor variant and
therefore, not included for case-control association.
In a univariate logistic regression analysis, keeping disease
status (DM or CRI) as dependent variable and all the gen-
otypes as independent variables, we observed a significant
association of the genotype GA (OR 1.95, CI 1.07–3.55, p
= 0.028) of 59029 G>A SNP with CRI. In a multiple logis-
tic regression analysis keeping disease status (DM or CRI)
as dependent variable and all the genotypes and crucial
clinical parameters as independent variables no associa-
tion of any of the polymorphisms or clinical parameters
with CRI was observed. Pair wise interactions tested
between different SNPs using logistic regression were not
found to be significantly associated with diabetic kidney
disease.
An additional, sub-analysis of diabetic CRI category using
retinopathy status (proliferative vs. non-proliferative) as
dependent variable and genotypes (all the polymor-
phisms analysed in this study) as independent variables
was performed using univariate logistic regression (Table
3). A compound group of genotypes 'GA and AA' of SNP
G>A -800 was found to confer predisposition in only
those diabetic CRI patients with proliferative retinopathy
(OR 3.03, CI 1.08–8.50, p = 0.035).
Discussion
Chronic renal insufficiency due to diabetes is the most fre-
quent cause of death due to end stage renal disease and
thus a major health concern world over [23]. Contempo-
rary evidences both from in vitro and in vivo studies in
experimental animals and renal biopsy specimens from
patients with progressive diabetic renal disease suggest
that cytokines play crucial role in development and pro-
gression of diabetic kidney disease [24-26]. Moreover,
results from our previous report [3] suggested that theBMC Medical Genetics 2007, 8:20 http://www.biomedcentral.com/1471-2350/8/20
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effect of RAAS may not be mediated through modulation
of hypertension as a crucial mechanism for development
of CRI but it may operate by stimulation of inflammatory
genes. Therefore, in this case-control study genetic contri-
bution of nine SNPs from TGFβ1, TNFα, CCR2 and CCR5
genes for CRI among individuals with type2 diabetes have
been analysed. We observed a significant allelic associa-
tion of allele "A" of SNP 59029 G>A in chemokine recep-
tor-5 gene with diabetic CRI.
Neither of the two promoter SNPs (G>A -800 and C>T -
509) of TGFβ1 gene showed association with CRI in this
study. These SNPs have not been tested for association
with diabetic nephropathy in any other population and
thus no comparison is possible. However, a study
reported a significant association of C>T-509 (p = 0.02)
SNPs in TGFβ1 gene polymorphisms with chronic kidney
failure in European population [27]. Another study,
which investigated association of two polymorphisms
Table 2: Allele and genotype frequencies (F) of SNPs and their association status with chronic renal insufficiency
SNPs Allele frequency Genotype frequency Association
DM
F (* n)
CRI
F (* n)
DM
F (** n)
CRI
F (** n)
Allele
(df = 1)
Genotype
(df = 2)
TGFβ1
G>A (-800)
G = 0.93 (418)
A = 0.07 (32)
G = 0.91 (356)
A = 0.09 (72)
GG = 0.87 (196)
GA = 0.12 (27)
AA = 0.01 (3)
GG = 0.84(165)
GA = 0.15 (29)
AA = 0.01 (2)
χ2 = 0.60;
P = 0.44
χ2 = 1.16;
P = 0.56
TGFβ1
C>T (-509)
C = 0.875 (388)
T = 0.125 (112)
C = 0.84 (330)
T = 0.16 (124)
CC = 0.77 (171)
CT = 0.21 (47)
TT = 0.02 (4)
CC = 0.72 (141)
CT = 0.24 (47)
TT = 0.04 (8)
χ2 = 1.24;
P = 0.27
χ2 = 1.23;
P = 0.54
TNFα
G>A (-308)
Promoter
G = 0.93 (416)
A = 0.07 (32)
G = 0.96 (376)
A = 0.04 (16)
GG = 0.87 (195)
GA = 0.12 (27)
AA = 0.01 (2)
GG = 0.91 (178)
GA = 0.08 (16)
AA = 0.01 (2)
χ2 = 2.31;
P = 0.13
χ2 = 2.43;
P = 0.12
CCR2
C>T
Val64Ile
C = 0.91 (410)
T = 0.09 (40)
C = 0.94 (368)
T = 0.06 (24)
CC = 0.84 (189)
CT = 0.15 (34)
TT = 0.01 (2)
CC = 0.90 (176)
CT = 0.09 (18)
TT = 0.01 (2)
χ2 = 2.73;
P = 0.10
χ2 = 2.87;
P = 0.24
CCR
5G>A (59029)
G = 0.46 (208)
A = 0.54 (242)
G = 0.38 (148)
A = 0.62 (244)
GG = 0.21 (47)
GA = 0.49 (111)
AA = 0.30 (67)
GG = 0.14 (27)
GA = 0.48 (94)
AA = 0.38 (75)
χ2 = 5.13;
P = 0.02
χ2 = 5.22;
P = 0.07
* Number of respective alleles, and ** genotypes in the study population.
Table 1: SNPs in TGFβ1, TNFα, CCR2 and CCR5 genes, their location, primer sequences, PCR conditions and restriction enzyme with 
product sizes.
Polymorphism Primer sequence Product size (bp) Annealing temp./restriction enzyme/allele sizes
TGFβ1
G>A (-800)
Promoter
F: 5' GGCAGTTGGCGAGAACAGT-3'
R: 5' ACCCAGAACGGAAGGAGAGT3'
600 57°C/Tai I/
G = 199, 401
A = 600
TGFβ1
C>T (-509)
Promoter
F: 5'-GGCAGTTGGCGAGAACAGT-3'
R: 5'-ACCCAGAACGGAAGGAGAGT-3'
600 57°C/Eco 8I1/
C = 489,111
T = 600
TGFβ1
Arg25Pro
Exon 1
F: 5'TTC CCT CGA GGC CCT CCT A3'
R: 5' CAC AGC AGC GGT AGC AGC TG3'
294 61°C/Sac II/
G = 202,67,25
C = 269,25
TGFβ1
Tyr81His
Exon 2
F: 5' CCAGATCCTGTCCAAGCTG3'
R: 5' TGGGTTTCCACCATTAGCAC3'
198 57°C/Rsa I/
T = 89,109
C = 198
TGFβ1
Thr263Ile
Exon 5
F: 5' CACCAAAGCAGGGTTCACTA3'
R: 5' ATCCAGGCTACAAGGCTCA3'
238 58°C/Fok I/
C = 238
T = 84, 154
TNFα
G>A -308
Promoter
F:5'AGGCAATAGGTTTTGAGGGcCAT3'
R:5'GGGACACACAAGCATCAAGGATAC3'
146 37°C/Nco I/
G = 146
A = 122, 24
CCR2
Val64Ile
Exon 1
F: 5'TTG TGG GCA ACA TGA TGG3'
R: 5'GCA TTC CCA AAG ACC CAC TC3'
163 57°C/BsaBI/
T = 163
C = 145,18
CCR5
G>A (59029)
Promoter
F: 5' CAG TCA ACC TGG GCA AAG CC3'
R: 5' AGC TTT GGT CCT GAG AGT CC3'
453 57°C/Bst 1286I/
G = 408, 45
A = 453
CCR5
Δ32
Promoter
F:5' GAAGTTCCTCATTACACCTGCAGCTCTC3'
R:5' CTTCTTCTCATTTCGACACCGAAGCAG AG3'
174/142 55°C/
1 = 174
2 = 142BMC Medical Genetics 2007, 8:20 http://www.biomedcentral.com/1471-2350/8/20
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inTGFβ1 gene, reported a significant association of
Arg25Pro inTGFβ1 gene with end-stage renal disease [28].
However, in our population since SNP Arg25Pro was
found to be a minor variant (with frequency of variant
allele = 0.01, unpublished data), it was non-informative.
Lack of association of CCR2 Val64Ile SNP in our study is
similar to other reports from Japanese population [14]. As
for association of CCR5 gene polymorphisms with CRI,
we observed a strong trend of association of 59029 G>A
SNP. This is in conformity with two other available
reports of association of this marker with DN among Jap-
anese population [14,29]. Though the allele 'A' is pre-
dominant in both control (DM) and case (CRI) groups, in
our sample set, the allele frequency is significantly higher
in CRI group (P = 0.02) and seems to be predisposing
based on OR estimates (OR: 1.39; CI: 1.04–1.84). An
enhanced expression of CCR5 by peripheral blood mono-
nuclear cells has been seen in individuals with the CCR5
59029A-genotype [30,31], thereby suggesting that the
genotype could regulate CCR5 gene expression. This fur-
ther corroborates our observation of association of allele
'A' with the disease. Considering the important role of
CCR5 gene in macrophage infiltration into glomerulus
and interstitium, our observation of association of pro-
moter SNP in seems exciting but in view of the sub-opti-
mal power of the sample analysed (G = 29%), a
replication study seems warranted.
Following analysis on the two sub groups of CRI patients,
one with and the other without proliferative retinopathy
(PR), a compound group of genotypes 'GA and AA' of SNP
G>A -800 in TGFβ1 gene was found to confer predisposi-
tion (P = 0.035; OR: 3.028; CI: 1.079–8.50) only in those
CRI patients with proliferative retinopathy (Table 3).
TGFβ1 gene has been known to influence almost every
pathway implicated in development of diabetic CRI [32].
Therefore, considering that TGFβ1 plays a very crucial role
in diabetic CRI progression and development, our finding
seems promising. However, due to relatively small sample
size after sub-grouping in this analysis, we would be cau-
tious in interpreting our results.
Conclusion
In conclusion, our results suggest that 59029 G>A SNP in
CCR5 gene may play a role in CRI susceptibility in the
Asian Indian population.
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